PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 9, 20260 citations

Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.

View Full Paper
AAA. Avogaro

Key Points

  • The aim is to assess the effects of incretin therapies on cardiovascular health in diabetes and obesity.
  • Examined challenges of incretin therapies including side effects and adherence issues.
  • Discussed the role of next-generation agents like triple agonists.
  • Highlighted the importance of lifestyle interventions for managing diabetes and obesity.
  • Incretin therapies improve cardiometabolic outcomes but present gastrointestinal side effects.
  • Adherence to treatment remains a significant challenge for patients.
  • Lifestyle modifications are crucial for sustained management of diabetes and cardiovascular conditions.

Abstract

While incretin therapies represent a transformative advancement in cardiometabolic care, challenges remain-including gastrointestinal side effects, adherence issues, lean mass loss and cost. As next-generation agents (e.g. triple agonists) advance, lifestyle interventions remain essential for durable, management of diabetes, obesity and associated cardiovascular conditions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

A. Avogaro (2026) studied this question.

synapsesocial.com/papers/69897a35f0ec2af6756e895ahttps://doi.org/10.1111/eci.70184
Ask AI
Helpful
Bookmark
Share
View Full Paper